LONDON, March 19, 2026 /PRNewswire/ -- The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and projected to reach US$ 1,081.9 million by 2033, with a CAGR of 8.8% over the forecast period. This growth comes from increasing infertility rates, advances in genetic analysis technologies, and heightened awareness about hereditary diseases among prospective parents. Preimplantation genetic tests provide crucial insights that guide embryo selection, helping improve pregnancy outcomes and reducing miscarriage risks. Market dynamics show continued technological progress and expanding access to fertility care, supporting broader adoption worldwide.
Key Highlights
- The global preimplantation genetic testing market is projected to reach US$ 1,081.9 Mn by 2033, expanding at a CAGR of 8.8% during the forecast period.
- Rising infertility rates and increasing maternal age are primary growth drivers, significantly boosting IVF and PGT adoption worldwide.
- Kits dominate the product segment, accounting for over 55% market share in 2026, supported by standardized workflows and automation compatibility.
- North America leads the market, driven by advanced IVF infrastructure and strong clinical adoption.
- Asia Pacific is projected to witness the fastest growth, fueled by expanding fertility clinics and supportive healthcare policies in China and India.
Request a Sample: https://www.persistencemarketresearch.com/samples/34757
Rising Infertility and Advanced Maternal Age Boost Market Growth
Globally, delayed childbearing has increased infertility rates, heightening demand for assisted reproductive technologies (ART) including IVF. In England and Wales, the average age of first-time mothers rose from 23 in 1970 to 29 in 2020, while IVF procedures accounted for over 99% of ART cycles. In the U.S., around 16.6% of IVF cycles now involve PGT to screen embryos for chromosomal abnormalities, mitigating genetic risks. This trend fuels demand for reliable testing, with clinics adopting NGS and advanced embryo biopsy techniques to enhance accuracy and treatment outcomes. Rising awareness of hereditary conditions and regulatory frameworks in countries such as India under the PCPNDT Act further support market expansion. Fertility clinics increasingly integrate PGT into standard IVF protocols, enabling couples to make informed decisions and achieve higher live birth rates.
Technological Innovations and Automation Improve IVF Outcomes
Advancements in genetic technologies, such as next-generation sequencing (NGS) and AI-assisted embryo assessment, are transforming the PGT market. NGS offers comprehensive chromosome screening, boosting clinical pregnancy rates from 45.6% to 54.4% and live birth rates from 30.9% to 52.1% in studies of advanced maternal age patients. AI-driven image analysis predicts embryo viability with high accuracy, reducing diagnostic errors. Non-invasive PGT methods using cell-free DNA further minimize embryo damage while maintaining precision. Automation and integrated lab platforms streamline workflows, enhancing efficiency and reducing turnaround times. Clinics in North America and Europe are investing in digitalized PGT solutions, enabling personalized IVF treatments and improving patient outcomes.
Key Highlight: AI-Enabled PGT Advancements by CooperSurgical and Igenomix
- A notable development in the Preimplantation Genetic Testing (PGT) market is the advancement of AI-integrated genetic screening platforms by CooperSurgical and Igenomix. CooperSurgical's PGTai? Technology Platform applies artificial intelligence and machine-learning algorithms to embryo biopsy data, supporting enhanced interpretation of PGT-A results. Meanwhile, Igenomix offers Smart PGT-A and Smart PGT-A Plus, which incorporate predictive algorithms to provide deeper chromosomal analysis and embryo assessment. These innovations aim to improve embryo selection processes and support informed clinical decision-making in IVF treatments.
- CooperSurgical brings extensive expertise in IVF laboratory technologies and reproductive solutions, while Igenomix contributes advanced genetic testing capabilities and bioinformatic analysis. Igenomix operates as part of the Vitrolife Group, strengthening its integration of genetics and embryology solutions. Both companies emphasize accuracy, data-driven insights, and workflow efficiency within fertility clinics. Their platforms are designed to provide reliable, standardized genetic reporting while supporting embryologists with AI-backed interpretation tools.
- These advancements address key challenges in IVF, including embryo selection uncertainty and variability in genetic result interpretation. By incorporating algorithm-based analysis, the technologies aim to enhance consistency, reduce subjectivity, and streamline laboratory operations. The integration of AI into PGT workflows reflects a broader industry shift toward precision-guided reproductive medicine and data-supported embryo viability assessment.
This signals accelerating adoption of AI-driven reproductive genetics solutions. Fertility clinics are increasingly prioritizing platforms that combine laboratory automation, genetic analytics, and predictive modeling. The growing use of AI-enabled PGT technologies sets a competitive benchmark in the market, encouraging further innovation focused on clinical accuracy, operational efficiency, and improved patient outcomes.
Request customization, ask for expert consulting, access a sample report, or simply express your interest-our team will assist you with the right insights and solutions:https://www.persistencemarketresearch.com/request-customization/34757
Segmentation Insights: Kits Segment Emerge as the Cornerstone of Growth
Kits lead the preimplantation genetic testing (PGT) market, supported by their standardized workflow, pre-validated reagents, and compatibility with next-generation sequencing platforms. Their pre-validated reagents and optimized protocols reduce human error and minimize reliance on highly specialized expertise, supporting wider adoption across fertility clinics. Their compatibility with automated systems and growing availability across advanced and emerging healthcare markets continue to strengthen segment growth. Recent developments around workflow optimization and integrated testing solutions further reinforce the strategic importance of kits within the PGT landscape.
Regional Insights: North America Leads Global PGT Adoption While Asia Pacific Emerges as the Fastest-Growing Innovation Hub
North America dominates the global preimplantation genetic testing (PGT) market, accounting for the largest revenue share, led by the strong performance of the U.S. market. Growth across the region is supported by advanced IVF infrastructure, high clinical adoption of genetic screening, favorable reimbursement frameworks, and substantial investment in genomics research. The presence of leading fertility networks and diagnostic innovators such as CooperSurgical strengthens technological advancement and commercial scalability. Rising maternal age and increasing prevalence of inherited disorders further sustain demand for early embryo screening. Meanwhile, Asia Pacific represents the fastest-growing region, driven by expanding access to fertility treatments, rising awareness of assisted reproductive technologies, and supportive government initiatives in China, India, and Japan. Rapid urbanization, healthcare infrastructure upgrades, and the emergence of cost-effective regional kit manufacturers are improving affordability, positioning Asia Pacific as a high-potential growth engine for the PGT market through 2033.
Key Players and Business Strategies
Leading players include CooperSurgical, Igenomix, Illumina, Fulgent Genetics, and Natera.
- CooperSurgical focuses on AI-integrated IVF solutions, enhancing procedural efficiency.
- Igenomix invests in automated genetic analysis platforms to expand clinic reach globally.
- Illumina emphasizes NGS-based PGT kits, enhancing test accuracy and throughput.
- Fulgent Genetics targets personalized IVF testing with rapid-result services.
- Natera develops non-invasive PGT solutions, minimizing embryo risk while ensuring precision.
Strategies across the market emphasize digital integration, personalized medicine, automation, and partnerships with fertility clinics to capture growing demand.
Buy Now:https://www.persistencemarketresearch.com/checkout/34757
Market Segmentation
By Product
- Kits
- Reagents and Consumables
By Technology
- Next-Generation Sequencing
- Fluorescence In Situ Hybridization
- Polymerase Chain Reaction
- Single-Nucleotide Polymorphism
- Comparative Genomic Hybridization
By Application
- Aneuploidy
- X-Linked Disorders
- Structural Chromosomal Abnormalities
- Single Gene Disorders
- Gender Identification
- HLA Typing for Stem Cell Transplants
By Distribution Channel
- Hospitals
- Fertility Clinics
- Diagnostic Laboratories
- Academic & Research Institutions
- Others
Related Reports of Biotechnology Market Reports
Histology and Cytology Consumables Market by Product (Kits & Reagents, Stains & Dyes, Enzymes, Fixatives, and Others), by Application (Clinical Diagnostics, Molecular Diagnostic Studies, Cell Signaling Studies, Epigenetics & Sequencing Studies, Drug Discovery & Development, and Research Applications) End-user (Hospitals, Diagnostic Laboratories, Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations (CROs), and Academic & Research Institutes), and Regional Analysis from 2026 to 2033
Hemato Oncology Testing Market by Product (Assay Kits, Reagents, Instruments / Platforms, Software & Services), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Flow Cytometry, Immunohistochemistry (IHC), Others), Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Others), End-user, and Regional Analysis from 2026 - 2033
Rapid Microbiology Testing Market by Product (Instruments, Reagents & Kits, Consumables, Software & Services), by Technology (Nucleic acid-based, Growth-based, Immunoassays & biosensors, ATP bioluminescence, Flow cytometry), by Application (Clinical diagnostics, Pharmaceutical & biologics testing, Food & beverage safety, Environmental testing, Cosmetics & personal care, Research & academic use), End-user and Regional Analysis, 2026 - 2033
Radiopharmaceutical Manufacturing Market by Radioisotope (Technetium-99m, Other), Technology (Cyclotron-based Manufacturing, Other), Application (Oncology, Others), End-user, and Regional Analysis for 2026 - 2033
Hydrogel-based Drug Delivery System Market by Source Type (Natural, Synthetic, Hybrid), Route of Delivery (Subcutaneous, Ocular, Others), Application (Cardiology, Others), End-user (Hospitals, Specialty Clinics, Others), and Regional Analysis for 2026 - 2033
CRISPR Gene-Editing Market by Product (Kits & Enzymes, Libraries, Others), Service (gRNA Design and Vector Construction, Cell Line Engineering, Screening Services, Other), Application, and Regional Analysis, 2026 - 2033
Extracellular Matrix Patches Market by Source (Porcine, Bovine, Others), by Application (Cardiac Repair, Vascular Repair, Soft Tissue Repair, Dural Repair, Orthopedic Repair, Wound Healing), End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), by Regional Analysis, 2026 - 2033
Platelet Rich Plasma Market by Product (Pure Platelet Rich Plasma (Pure PRP), Leukocyte-rich Platelet Rich Plasma (L-PRP), Platelet Rich Fibrin (PRF), and Others), by Application (Orthopedics, Neurology, Cosmetics, Wound Care, and Others) by End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers, and Academic and Research Institutes), and Regional Analysis from 2026 - 2033
Cellular Pathology Market by Product Type (Diagnostic Kits, Others), Technology (Digital Pathology, Immunohistochemistry, Others), Application (Cancer Diagnostics, Infectious Diseases, Others), End-user, and Regional Analysis for 2026 - 2033
3D Cell Culture Market by Product (Medical Imaging Equipment, Operating Room & Surgical Equipment, Critical Care Devices, Patient Monitoring Devices, Neurology Devices, Cardiovascular Devices, Endoscopy Devices, and Others), Application (Cardiology, Neurology, Oncology, Orthopedics, Gynecology, and Others), End-user (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers (ASCs), and Specialty Clinics), and Regional Analysis from 2026 - 2033.
About Persistence Market Research:
At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviours, and competitive intelligence! For over a decade, we've been at the forefront of delivering game-changing analytics and research that drive businesses toward growth.
Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today's competitive environment.
Contact
Ritika Khandelwal
Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ
+44 203-837-5656
United Kingdom
USA Phone - +1 646-878-6329
Email: sales@persistencemarketresearch.com
Logo: https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/preimplantation-genetic-testing-market-to-reach-us-1-081-9-million-by-2033-amid-rising-ivf-adoption-and-technological-innovation---persistence-market-research-302718707.html
